DUVAL PHARMACEUTICS CONSULTING: what changed
DUVAL PHARMACEUTICS CONSULTING
Largest movements
- Receivables within one year +€24,279
up €24,279 (+249%), from €9,749 to €34,028
of which Trade receivables: +€24,410
- Tangible fixed assets -€11,227
down €11,227 (-43.8%), from €25,655 to €14,428
of which Other tangible fixed assets: -€10,118
- Cash +€9,775
up €9,775 (+12.0%), from €81,286 to €91,061
mainly Net result for the year (+€41,941) and Depreciation (+€11,818)
- Intangible fixed assets +€7,256
up €7,256 (+82.2%), from €8,827 to €16,082
- Reserves +€41,941
up €41,941 (+44.5%), from €94,262 to €136,204
of which Distributable reserves: +€41,941
- Current portion of long-term debt -€11,844
down €11,844 (-100%), from €11,844 to €0
- Depreciation -€11,637
down €11,637 (-49.6%), from €23,455 to €11,818
- Gross operating margin +€9,568
up €9,568 (+13.2%), from €72,215 to €81,783
- Taxes +€4,590
up €4,590 (+28.8%), from €15,917 to €20,506
- Other operating charges +€3,526
up €3,526 (+195%), from €1,807 to €5,333
- Financial charges +€1,922
up €1,922 (+95.9%), from €2,005 to €3,926
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €127,118 | €156,594 | +€29,476 | +23.2% |
| Fixed assets | 21/28 | €34,481 | €30,510 | -€3,971 | -11.5% |
| Intangible fixed assets | 21 | €8,827 | €16,082 | +€7,256 | +82.2% |
| Tangible fixed assets | 22/27 | €25,655 | €14,428 | -€11,227 | -43.8% |
| Furniture and vehicles | 24 | €4,023 | €2,914 | -€1,109 | -27.6% |
| Other tangible fixed assets | 26 | €21,631 | €11,514 | -€10,118 | -46.8% |
| Current assets | 29/58 | €92,636 | €126,084 | +€33,447 | +36.1% |
| Amounts receivable within one year | 40/41 | €9,749 | €34,028 | +€24,279 | +249% |
| Trade receivables | 40 | €8,928 | €33,338 | +€24,410 | +273% |
| Other amounts receivable | 41 | €821 | €690 | -€131 | -16.0% |
| Cash at bank and in hand | 54/58 | €81,286 | €91,061 | +€9,775 | +12.0% |
| Deferred charges and accrued income | 490/1 | €1,602 | €995 | -€607 | -37.9% |
| Total equity and liabilities | 10/49 | €127,118 | €156,594 | +€29,476 | +23.2% |
| Equity | 10/15 | €106,662 | €148,604 | +€41,941 | +39.3% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €94,262 | €136,204 | +€41,941 | +44.5% |
| Non-distributable reserves | 130/1 | €0 | - | = | |
| Reserves not available under the articles | 1311 | €0 | - | = | |
| Distributable reserves | 133 | €94,262 | €136,204 | +€41,941 | +44.5% |
| Profit (loss) carried forward | 14 | €0 | - | = | |
| Amounts payable | 17/49 | €20,455 | €7,990 | -€12,465 | -60.9% |
| Amounts payable after more than one year | 17 | €0 | - | = | |
| Financial debts | 170/4 | €0 | - | = | |
| Amounts payable within one year | 42/48 | €20,455 | €7,990 | -€12,465 | -60.9% |
| Current portion of amounts payable after more than one year | 42 | €11,844 | €0 | -€11,844 | -100% |
| Financial debts | 43 | €346 | €128 | -€218 | -63.0% |
| Credit institutions | 430/8 | €346 | €128 | -€218 | -63.0% |
| Trade debts | 44 | €2,551 | €2,225 | -€326 | -12.8% |
| Suppliers | 440/4 | €2,551 | €2,225 | -€326 | -12.8% |
| Taxes, remuneration and social security | 45 | €5,715 | €5,638 | -€77 | -1.3% |
| Taxes | 450/3 | €5,715 | €5,638 | -€77 | -1.3% |
| Other amounts payable | 47/48 | €0 | - | = | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €23,455 | €11,818 | -€11,637 | -49.6% |
| Other operating charges | 640/8 | €1,807 | €5,333 | +€3,526 | +195% |
| Gross operating margin | 9900 | €72,215 | €81,783 | +€9,568 | +13.2% |
| Operating profit (loss) | 9901 | €46,953 | €64,632 | +€17,679 | +37.7% |
| Financial income | 75/76B | €1,632 | €1,742 | +€110 | +6.7% |
| Recurring financial income | 75 | €1,632 | €1,742 | +€110 | +6.7% |
| Financial charges | 65/66B | €2,005 | €3,926 | +€1,922 | +95.9% |
| Recurring financial charges | 65 | €2,005 | €3,926 | +€1,922 | +95.9% |
| Profit (loss) for the period before taxes | 9903 | €46,580 | €62,448 | +€15,867 | +34.1% |
| Income taxes | 67/77 | €15,917 | €20,506 | +€4,590 | +28.8% |
| Profit (loss) for the period | 9904 | €30,663 | €41,941 | +€11,278 | +36.8% |
| Profit (loss) for the period to be appropriated | 9905 | €30,663 | €41,941 | +€11,278 | +36.8% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 30 September 2024 and 30 September 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.